A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Consumer medication information leaflet for atenolol





Consumer Medicines Information - Terry White Chemists Atenolol

10/22/2014
05:03 | Author: Kate Thompson

Consumer medication information leaflet
Consumer Medicines Information - Terry White Chemists Atenolol

Index of Consumer Medicines Information leaflets of prescription and over-the-counter medicines - Terry White Chemists Atenolol Tablets.

l your doctor immediay if you notice any of the following:

After a heart attack, you may have complications such as an irregular heart beat or an increased chance of having another heart attack.

Weight:. Your doctor may advise you to limit your alcohol intake.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking atenolol.

Comments (1)Read more



Atenolol Indications, Side Effects, Warnings

8/21/2014
03:34 | Author: Evan Martin

Consumer medication information leaflet
Atenolol Indications, Side Effects, Warnings

Easy to read patient leaflet for atenolol. Includes indications these apply to you. Slideshow: Living with Your Migraines: Tips for Treatment and Prevention Ask you doctor for more information. If you have a. Consumer resources. Atenolol.

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome: Check with your doctor if any of these most COMMON side effects persist or become bothersome:.

High Blood Pressure lisinopril, amlodipine, metoprolol, losartan, hydrochlorothiazide, furosemide, More.

Approval History Calendar Drug history at FDA.

Cold fingers and toes; diarrhea; dizziness; drowsiness; nausea; tiredness or weakness.

Only your health care provider has the knowledge and training to decide which medicines are right for you.

Comments (2)Read more

Consumer medication information in the United States, Europe, and

6/20/2014
01:49 | Author: Cole Thomas

Consumer medication information leaflet
Consumer medication information in the United States, Europe, and

Intervention Patient information leaflets for atenolol, glyburide (glibenclamide), atorvastatin, and nitroglycerin (glyceryl trinitrate) from the United States, United.

The Australian leaflets performed well across all criteria, whereas the U.S. Conclusion Leaflet quality varied more among the three countries than within each country, reflecting the regulatory context. A repeat survey is needed to assess whether new legislation and guidance in all three countries successfully addresses the shortcomings identified. OR. leaflets had significant shortcomings with the omission of vital information for the safe and effective use of the medications.

Objective To evaluate the quality of patient information leaflets provided with dispensed medications in the United States, United Kingdom, and Australia.

Register for a FREE limited account to benefit from personalization features such as alerts.

Participants Not applicable.

Comments (3)Read more

Consumer Medication Information In the United

4/19/2014
01:52 | Author: Evan Martin

Consumer medication information leaflet
Consumer Medication Information In the United

By Jonathan Silcock in Consumer Health Information and Medicines Intervention: Patient information leaflets for atenolol, glyburide.

Need an account? Click here to sign up.

Follow other people in your field.

Download PDFs for over 3.5 Million papers.

Before we can start your download, please take a moment to join our community of 14,453,720 academic researchers.

See analytics on your profile & papers.

Share your papers with other researchers.

Enter the address you signed up with and we'll you a reset link.

Loading Preview.

There were some errors with your registration:. We're sorry.

Comments (0)

Consumer medication information in the United - ResearchGate

2/18/2014
03:25 | Author: Kate Thompson

Consumer medication information leaflet
Consumer medication information in the United - ResearchGate

Patient information leaflets for atenolol, glyburide (glibenclamide), atorvastatin, and nitroglycerin (glyceryl trinitrate) from the United States, United Kingdom, and.

The Australian leaflets performed well across all criteria, whereas the U.S. ABSTRACT To evaluate the quality of patient information leaflets provided with dispensed medications in the United States, United Kingdom, and Australia. Not applicable. The lower U.K. leaflets achieved 50% or less adherence for contraindication and precaution information. consensus criteria for both clinical information and general criteria, including the design of the leaflets. The U.S. The U.S. Leaflet quality varied more among the three countries than within each country, reflecting the regulatory context. A repeat survey is needed to assess whether new legislation and guidance in all three countries successfully addresses the shortcomings identified. Leaflets from Australia received a mean overall score of 90% (range 83%-94%) adherence with criteria, those from the United Kingdom a score of 81% (range 73%-84%), and those from the United States a score of 68% (range 65%-77%). Patient information leaflets for atenolol, glyburide (glibenclamide), atorvastatin, and nitroglycerin (glyceryl trinitrate) from the United States, United Kingdom, and Australia. Leaflets were evaluated against U.S. leaflets also scored poorly (60%) for legibility and comprehensibility. United States, United Kingdom, and Australia. Omissions included warnings about preexisting allergy and illness and information about drug interactions. leaflets had significant shortcomings with the omission of vital information for the safe and effective use of the medications. Quantitative survey by an expert panel. score reflected shortcomings in information about how to use and monitor the medications (46% adherence) and on adverse drug reactions (64%), largely due to the lack of clear advice about urgency of action in relation to adverse drug reactions.

Comments (0)